-
公开(公告)号：US11484534B2
公开(公告)日：2022-11-01
申请号：US15431906
申请日：2017-02-14
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Andrew L. Campbell , Sandeep Dutta , Chih-Wei Lin , Wei Liu , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki , Tianli Wang
IPC: A61K31/498 , A61K31/454 , A61K38/05 , A61K38/06
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20150164976A1
公开(公告)日：2015-06-18
申请号：US14628849
申请日：2015-02-23
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Scott C. Brun , Daniel E. Cohen , Emily O. Dumas , Sandeep Dutta , Amit Khatri , Cheri E. Klein , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki
IPC: A61K38/07 , A61K31/427 , A61K31/7056 , A61K31/513 , A61K38/05
CPC classification number: A61K38/07 , A61K31/402 , A61K31/4025 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/4709 , A61K31/497 , A61K31/513 , A61K31/675 , A61K31/7056 , A61K31/7072 , A61K38/05 , A61K38/12 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
-
公开(公告)号：US20140107017A1
公开(公告)日：2014-04-17
申请号：US14138515
申请日：2013-12-23
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein , Thomas J. Podsadecki
IPC: A61K38/12 , A61K31/427 , A61K31/7072 , A61K31/4184 , A61K31/513 , A61K31/4025
CPC classification number: A61K38/07 , A61K31/402 , A61K31/4025 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/4709 , A61K31/497 , A61K31/513 , A61K31/675 , A61K31/7056 , A61K31/7072 , A61K38/05 , A61K38/12 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。
-
公开(公告)号：US20140107016A1
公开(公告)日：2014-04-17
申请号：US14138449
申请日：2013-12-23
Applicant: AbbVie Inc.
Inventor： Barry M. Bernstein , Rajeev M. Menon , Amit Khatri , Sven Mensing , Sandeep Dutta , Daniel E. Cohen , Scott C. Brun , Walid M. Awni , Emily O. Dumas , Cheri E. Klein , Thomas J. Podsadecki
IPC: A61K38/12 , A61K31/427 , A61K31/7072 , A61K31/4184 , A61K31/4025 , A61K31/513
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4184 , A61K31/427 , A61K31/473 , A61K31/513 , A61K31/7072 , A61K38/05 , A61K38/06 , A61K38/12 , A61K45/06 , G06F17/10 , G06F19/12
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
-
公开(公告)号：US20250057837A1
公开(公告)日：2025-02-20
申请号：US18935760
申请日：2024-11-04
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Andrew Campbell , Sandeep Dutta , Chih-Wei Lin , Wei Liu , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki , Tianli Wang
IPC: A61K31/498 , A61K31/454 , A61K31/7056 , A61K31/7072 , A61P31/14 , G06F7/00 , G06F16/215 , G06F16/23 , G06F16/25
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20230019186A1
公开(公告)日：2023-01-19
申请号：US17651187
申请日：2022-02-15
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： John Hayslip , Leanne M. Holes , Sven Mensing , Silpa Nuthalapati
IPC: A61K31/5377 , A61P35/00 , A61K31/52
Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
-
公开(公告)号：US20210023012A1
公开(公告)日：2021-01-28
申请号：US16837576
申请日：2020-04-01
Applicant: AbbVie Inc.
Inventor： Wei Liu , Hoi Kei Lon , Sven Mensing , Jeffrey Schmidt , Neha Thakre , Thin Yu Tu
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first type of film-coated granules which comprise 50 mg of Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second type of film-coated granules which comprise 20 mg of Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
公开(公告)号：US09452194B2
公开(公告)日：2016-09-27
申请号：US14503849
申请日：2014-10-01
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Scott C. Brun , Daniel E. Cohen , Emily O. Dumas , Sandeep Dutta , Amit Khatri , Cheri E. Klein , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki
IPC: A01N43/04 , A61K31/70 , A61K38/07 , A61K31/4025 , A61K31/4178 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/513 , A61K45/06 , A61K31/427 , A61K31/439 , A61K31/7056 , A61K31/7072 , A61K31/5377 , A61K38/06
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4178 , A61K31/427 , A61K31/439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/513 , A61K31/5377 , A61K31/7056 , A61K31/7072 , A61K38/06 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
-
公开(公告)号：US20150196615A1
公开(公告)日：2015-07-16
申请号：US14670734
申请日：2015-03-27
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Scott C. Brun , Daniel E. Cohen , Emily O. Dumas , Sandeep Dutta , Amit Khatri , Cheri E. Klein , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki
IPC: A61K38/07 , A61K38/05 , G06F17/10 , A61K45/06 , G06F19/12 , A61K31/513 , A61K31/427
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4184 , A61K31/427 , A61K31/473 , A61K31/513 , A61K31/7072 , A61K38/05 , A61K38/06 , A61K38/12 , A61K45/06 , G06F17/10 , G16B5/00
Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。
-
公开(公告)号：US20150024999A1
公开(公告)日：2015-01-22
申请号：US14503849
申请日：2014-10-01
Applicant: AbbVie Inc.
Inventor： Walid M. Awni , Barry M. Bernstein , Scott C. Brun , Daniel E. Cohen , Emily O. Dumas , Sandeep Dutta , Amit Khatri , Cheri E. Klein , Rajeev M. Menon , Sven Mensing , Thomas J. Podsadecki
IPC: A61K38/07 , A61K38/06 , A61K31/513 , A61K31/7056 , A61K31/427
CPC classification number: A61K38/07 , A61K31/4025 , A61K31/4178 , A61K31/427 , A61K31/439 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/513 , A61K31/5377 , A61K31/7056 , A61K31/7072 , A61K38/06 , A61K45/06 , A61K2300/00
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括给予受试者有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.018 seconds)
